← SynDRA
PANOBINOSTAT
SynDRA canonical compound SYN0016554 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · OTC |
|---|
| Primary target(s) | HDAC1 | HDAC2 | HDAC3 | HDAC4 | HDAC6 | HDAC7 | HDAC8 | HDAC9 |
|---|
| Mechanism of action | HDAC inhibitor |
|---|
| Indication | multiple myeloma |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- HDAC1
- HDAC2
- HDAC3
- HDAC4
- HDAC6
- HDAC7
- HDAC8
- HDAC9
- HDAC10
- HDAC11
- HDAC5
- BRD4
Mechanisms of action (all sources)
- HDAC1 INHIBITOR
- Histone deacetylase inhibitor
- HDAC3 INHIBITOR
- HDAC6 INHIBITOR
- HDAC2 INHIBITOR
- HDAC5 INHIBITOR
- HDAC7 INHIBITOR
- HDAC8 INHIBITOR
- HDAC11 INHIBITOR
- HDAC4 INHIBITOR
- HDAC9 INHIBITOR
- HDAC10 INHIBITOR
Drug classes
- Histone Deacetylase Inhibitors
- Histone Deacetylase Inhibitor
- Antineoplastic Agents
- Enzyme Inhibitors
- Cytochrome P450 2D6 Inhibitors
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- farydak
- panobinostat lactate
- panobinostat lactate anhydrous
- LBH-589
- LBH589
- Panobinostat hydrate
- Farydak
- Faridak
- LBH-589B
- NVP-LBH589
- NVP-LBH-589
- Panobinostat, NVP-LBH589, LBH589
- (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
- (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
- LBH 589
- Panobinostat (LBH589)
- (E)-N-Hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide
- NVP-LBH 589
- Panobinostat(LBH589)
- (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
- CHEBI:85990
- 9647FM7Y3Z
- 404950-80-7 (free base)
- Farydak (TN)
- (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
- 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-
- 2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-
- Panobinostat [INN]
- Panobinostat [USAN:INN]
- UNII-9647FM7Y3Z
- PANOBINOSTAT [MI]
- LBH589 - Panobinostat
- Panobinostat (USAN/INN)
- PANOBINOSTAT [USAN]
- N-Hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylaminomethyl]phenyl]-2(E)-propenamide
- PANOBINOSTAT [MART.]
- MLS006011216
- PANOBINOSTAT [WHO-DD]
Reported adverse events
- Arrhythmia
- ECG
- Fatigue
- Infection
- Neutropenia
- Thrombocytopenia
- Weight decreased
- Decreased appetite
- Asthenia
- Blood creatinine increased
- Death
- Hepatotoxicity
Look up PANOBINOSTAT in the interactive SynDRA portal →